drugset / Trial / NCT01861912
Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether compared with arsenic trioxide TACE alone, arsenic trioxide TACE and intravenous administration could further prolong the overall survival.
Timeline
- Start
- 2013-06
- Primary completion
- 2016-06
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | arsenic trioxide | Small molecule | 0.15 mg/kg | Intravenous |
| Background | lipiodol | Unknown | — | — |